Analysts See $-0.91 EPS for UroGen Pharma Ltd. (URGN)

July 14, 2018 - By Matthew Richard

Analysts expect UroGen Pharma Ltd. (NASDAQ:URGN) to report $-0.91 EPS on August, 13.They anticipate $0.21 EPS change or 30.00 % from last quarter’s $-0.7 EPS. After having $-0.88 EPS previously, UroGen Pharma Ltd.’s analysts see 3.41 % EPS growth. The stock decreased 2.67% or $1.31 during the last trading session, reaching $47.73. About 72,161 shares traded. UroGen Pharma Ltd. (NASDAQ:URGN) has risen 228.14% since July 14, 2017 and is uptrending. It has outperformed by 215.57% the S&P500.

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing therapies for urological pathologies. The company has market cap of $738.57 million. The Company’s lead product candidates, MitoGel and VesiGel are formulations of the chemotherapy drug Mitomycin C, a generic drug which is currently used off-label for urothelial cancer treatment only in a water formulation as an adjuvant, or supplemental post-surgery, therapy. It currently has negative earnings. The firm is developing its product candidates as chemoablation agents, which are designed to remove tumors by non-surgical means, to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, and low-grade bladder cancer.

More important recent UroGen Pharma Ltd. (NASDAQ:URGN) news were published by: which released: “UroGen Pharma Appoints Shawn Cline Tomasello to its Board of Directors” on July 10, 2018, also published article titled: “UroGen Pharma (URGN) Names Shawn Cline Tomasello to Board”, published: “Qwilt Appoints Yoni Mizrahi as Chief Financial Officer” on June 21, 2018. More interesting news about UroGen Pharma Ltd. (NASDAQ:URGN) was released by: and their article: “UroGen Pharma (URGN) Submits IND Application for UGN-102 for Treatment of Low-Grade Non-Muscle Invasive …” with publication date: July 11, 2018.

UroGen Pharma Ltd. (NASDAQ:URGN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.